Skip to content
Open access · CC-BY via OpenAlex

A role for metformin in the treatment of Dupuytren disease?

Alberto Baeri, Michaël Levraut, Serena Diazzi, Olivier Camuzard, Marianne Cegarra-Escolano, Marie-Anne Ploumellec, Thierry Balaguer, Julien Fassy, Roger Rezzonico, Savério Bellusci, Bernard P. Mari, Georges Vassaux

Biomedicine & Pharmacotherapy · 2022 · ▲ 1 citations

Abstract

Dupuytren disease (DD) is a hand-localized fibrotic disorder characterized by a scar-like, collagen-rich cord. Treatment usually comprises surgical removal of the cord, but is associated with a high relapse rate, in some cases requiring finger amputation. There is currently no consensual medical approach for treating DD. Numerous preclinical studies have highlighted antifibrotic properties of metformin, and the aim of this study was to assess a potential antifibrotic role of metformin in DD. Fibroblasts from DD cords (DF) and phenotypically normal palmar fascia (PF) were extracted from surgical specimens and cultured. The fibrotic status of DF and PF was compared at baseline, and under profibrotic (TGF-β stimulation) and antifibrotic (metformin stimulation) conditions, using quantitative RT-PCR, western blot, immunocytochemistry, and a functional fibroblast contraction assay. At baseline, DF showed higher levels of fibrotic markers and contraction capacity compared with PF. Both types of fibroblasts responded to TGF-β stimulation. Treatment of DF and PF with metformin did not affect basal levels of fibrotic markers and contraction but largely prevented their induction by TGF-β. In conclusion, our data show that metformin inhibits TGF-β-induced expression of fibrotic markers and contraction in hand-derived fibroblasts. This supports the case for a clinical trial to assess the repurposing of metformin as an adjuvant to surgery, to prevent, reduce, or delay recurrence in at-risk DD patients.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.biopha.2022.112930
Canonical
link ↗
Fetched
2026-10-08 MST

Cite this

APA
Baeri, A., Levraut, M., Diazzi, S., Camuzard, O., Cegarra-Escolano, M., Ploumellec, M., Balaguer, T., Fassy, J., Rezzonico, R., Bellusci, S., Mari, B.P., &amp; Vassaux, G. (2022). A role for metformin in the treatment of Dupuytren disease?. <em>Biomedicine & Pharmacotherapy</em>. https://doi.org/10.1016/j.biopha.2022.112930
Vancouver
Baeri A, Levraut M, Diazzi S, Camuzard O, Cegarra-Escolano M, Ploumellec M, et al. A role for metformin in the treatment of Dupuytren disease?. Biomedicine & Pharmacotherapy. 2022. doi:10.1016/j.biopha.2022.112930.
BibTeX
@article{alberto2022Arolef, title = {A role for metformin in the treatment of Dupuytren disease?}, author = {Alberto Baeri and Michaël Levraut and Serena Diazzi and Olivier Camuzard and Marianne Cegarra-Escolano and Marie-Anne Ploumellec and Thierry Balaguer and Julien Fassy and Roger Rezzonico and Savério Bellusci and Bernard P. Mari and Georges Vassaux}, journal = {Biomedicine & Pharmacotherapy}, year = {2022}, doi = {10.1016/j.biopha.2022.112930}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings